Estimated antiretroviral therapy coverage among people living with HIV in Sweden
Sweden: Estimated antiretroviral therapy coverage among people living with HIV was 95.0% in 2024. ▲ Rising
Estimated antiretroviral therapy coverage among people living with HIV in Sweden, 2000–2024
Source: World Health Organization, Global Health Observatory.
Analysis
Sweden recorded 95.0% for estimated antiretroviral therapy coverage among people living with hiv in 2024.
Compared with earlier readings it is down 1.0% on the previous year and up 3.3% over ten years.
Over the whole period, estimated antiretroviral therapy coverage among people living with hiv in Sweden peaked at 97.0% in 2019 and was at its lowest, 31.0%, in 2000.
That places Sweden 5th out of 143 countries with data for 2024, putting it in the top 10%.
The long-run direction has been consistently rising across the 25 years of available data.
Estimated antiretroviral therapy coverage among people living with HIV in Sweden, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 31.0% | — |
| 2001 | 33.0% | +6.5% |
| 2002 | 34.0% | +3.0% |
| 2003 | 43.0% | +26.5% |
| 2004 | 46.0% | +7.0% |
| 2005 | 48.0% | +4.3% |
| 2006 | 50.0% | +4.2% |
| 2007 | 59.0% | +18.0% |
| 2008 | 69.0% | +16.9% |
| 2009 | 75.0% | +8.7% |
| 2010 | 80.0% | +6.7% |
| 2011 | 83.0% | +3.8% |
| 2012 | 86.0% | +3.6% |
| 2013 | 89.0% | +3.5% |
| 2014 | 92.0% | +3.4% |
| 2015 | 94.0% | +2.2% |
| 2016 | 95.0% | +1.1% |
| 2017 | 96.0% | +1.1% |
| 2018 | 96.0% | +0.0% |
| 2019 | 97.0% | +1.0% |
| 2020 | 96.0% | -1.0% |
| 2021 | 95.0% | -1.0% |
| 2022 | 97.0% | +2.1% |
| 2023 | 96.0% | -1.0% |
| 2024 | 95.0% | -1.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 48.8% | 31.0% | 75.0% | 10 |
| 2010s | 90.8% | 80.0% | 97.0% | 10 |
| 2020s | 95.8% | 95.0% | 97.0% | 5 |
Countries ranked near Sweden
More health data for Sweden
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.8581 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,109 deaths per 1,000 people (2090)
- Number of infants who die before age 1 30 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.12 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0243 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.2 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is estimated antiretroviral therapy coverage among people living with hiv in Sweden?
- Estimated antiretroviral therapy coverage among people living with hiv in Sweden was 95.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest estimated antiretroviral therapy coverage among people living with hiv recorded in Sweden?
- The highest recorded value was 97.0% in 2019.
- What is the lowest estimated antiretroviral therapy coverage among people living with hiv recorded in Sweden?
- The lowest recorded value was 31.0% in 2000.
- How does Sweden rank for estimated antiretroviral therapy coverage among people living with hiv?
- Sweden ranks 5th out of 143 countries with data for 2024.
- Is estimated antiretroviral therapy coverage among people living with hiv rising or falling in Sweden?
- Over the last ten years it is up 3.3%. The long-run trend across the full record is rising.
- Where does this Sweden data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).